Cell and Gene Therapy Tools, and Reagents: Global Markets

Aug 2020| BIO208A| BCC Publishing

Report Highlights

The global market for life science tools should grow from $6.5 billion in 2019 to reach $9.0 billion by 2024 at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2019-2024.

Report Includes

  • 77 data tables
  • An overview of the global market for immunoassay-based cell and gene therapy tools, and reagents within the life sciences industry
  • Analyses of the global market trends, with data corresponding to market size for 2017-2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information about in vitro diagnostics (IVD), its background and importance of IVD testing
  • Discussion on prevalence of infectious disease, metabolic disorders and chronic ailments as drivers of immunoassay testing market
  • Description of recent technologies such as chemiluminescent immunoassays (CLIA), fluorescent immunoassays, multiplex assays and rapid diagnostic technologies
  • Evaluation of market potential for immunoassay-based cell and gene therapy tools and reagents, current market size and market forecast, and market share analysis of the leading players engaged
  • Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology
  • Company profiles of the key market participants, including Bio-Rad Laboratories, Cytiva Life Sciences, Luminex Corp., Millipore Sigma, Thermo Fisher Scientific and STEMCELL Technologies

Report Scope

The scope of this study encompasses an investigation of the markets cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. BCC Research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. BCC Research analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

Analyst Credentials

Todd Graham is an experienced scientist who has worked in a variety of settings throughout the biotechnology industry for more than 10 years as a key technical resource for a variety of businesses. Among his accomplishments are coordinating the roll out of a new test for a major clinical laboratory services provider, developing pre-clinical and clinical assays in support of pharmaceuticals and medical devices, and being a key team member in developing novel technologies for molecular diagnostics.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Cell and Gene Therapy Tools, and Reagents: Global Markets71 $2,750 Free
Chapter- 1: Introduction5Free DownloadFree
Chapter- 2: Summary and Highlights3$250Free
Chapter- 3: Market and Technology Background9$349Free
Chapter- 4: Market Breakdown by Region22$852Free
Chapter- 5: Market Breakdown by End User17$658Free
Chapter- 6: Government Regulations3$116Free
Chapter- 7: Patent Review/New Developments5$194Free
Chapter- 8: Analysis of Market Opportunities2$77Free
Chapter- 9: Company Profiles5$194Free
Cell and Gene Therapy Tools, and Reagents: Global Markets

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries

Need a custom data table, graph or complete report? Tell us more.